Predictive Markers in Chinese Growth Hormone Deficiency (GHD) Children Treated With Saizen®

• Conditions: Dwarfism, Pituitary; MedDRA version: 18.0Level: PTClassification code 10013883Term: DwarfismSystem Organ Class: 10028395 - Musculoskeletal and connective tissue disorders; Therapeutic area: Body processes [G] - Metabolic Phenomena [G03]

• Registration Number: EUCTR2015-001569-20-Outside-EU/EEA
• Lead Sponsor: Merck Serono Co., Ltd.

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Study Start: 2015-07-06
• Last Update Posted: 4 August 2015

Recruitment & Eligibility

• Status: A
• Sex: All
• Target Recruitment: 214

Inclusion Criteria

•Male and female subjects with documented pre-established diagnosis of GHD with a GH peak response of <10 microgram/liter (mcg/L) with 2 GH stimulation tests, without priming with estradiol
•Subjects with SGA defined as birth weight and/or length at least 2 standard deviations (SDs) below the mean for gestational age
•Subjects with prepubertal status according to Tanner
•Subjects with pre-established history of normal thyroid function or adequate substitution for at least 3 months
•Subjects with weight for stature within the population specific normal range (>5th and <95th percentiles) for gender
•Subjects with willingness and ability to comply with the protocol for the duration of the study
•Subjects whose parents or guardians written informed consent given before any study-related procedure that was not part of the subjects normal medical care, with the understanding that the subject or parent/guardian might withdraw consent at any time without prejudice to future medical care. If the child was old enough to read and write, a separate assent form was given

Are the trial subjects under 18? yes
Number of subjects for this age range: 205
F.1.2 Adults (18-64 years) no
F.1.2.1 Number of subjects for this age range
F.1.3 Elderly (>=65 years) no
F.1.3.1 Number of subjects for this age range

Exclusion Criteria

•Subjects who acquired GHD due to central nervous system tumor, trauma, infection, infiltration (documented by imaging), and history of irradiation or cranial surgery
•Subjects with previous treatment with GH, growth hormone releasing hormone (GHRH), anabolic steroids or any treatment affecting growth
•Subjects who had previous treatment with corticosteroids, except in case of topical or inhaled corticosteroid administration for atopic disease. Corticosteroids for hormonal substitution were also allowed if the condition and the treatment regimen had been stable for at least 3 months
•Subjects with severe associated pathology affecting growth such as malnutrition, malabsorption, or bone dysplasia
•Subjects with chronic severe kidney disease
•Subjects with chronic severe liver disease
•Subjects with chronic infectious disease
•Subjects with acute or severe illness during the previous 6 months
•Subjects with significant concomitant illness that would interfere with participation or assessment in this study
•Subjects who had active malignancy (except non-melanomatous skin malignancies that had undergone surgical excision and/or biopsy, diagnosis and treatment to resolution)
•Subjects with history or active idiopathic intra-cranial hypertension (benign intracranial hypertension or pseudo-tumor cerebri)
•Subjects with diabetes mellitus type I & II
•Subjects with any autoimmune disease
•Subjects who had previous screening failure in this study
•Subjects who had used an investigational drug or participated in another clinical study within the last 3 months

Study & Design

• Study Type: Interventional clinical trial of medicinal product
• Study Design: Not specified